-
1
-
-
79952717349
-
An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management
-
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 788-824
-
-
Raghu, G.1
Collard, H.R.2
Egan, J.J.3
-
2
-
-
20544443765
-
The clinical course of patients with idiopathic pulmonary fibrosis
-
Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-7.
-
(2005)
Ann Intern Med
, vol.142
, pp. 963-967
-
-
Martinez, F.J.1
Safrin, S.2
Weycker, D.3
-
3
-
-
0034520079
-
The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
-
Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-7. (Pubitemid 32051689)
-
(2000)
American Journal of Respiratory and Critical Care Medicine
, vol.162
, Issue.6
, pp. 2213-2217
-
-
Nicholson, A.G.1
Colby, T.V.2
Dubois, R.M.3
Hansell, D.M.4
Wells, A.U.5
-
4
-
-
0032851824
-
A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis
-
Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999;160:899-905. (Pubitemid 29442028)
-
(1999)
American Journal of Respiratory and Critical Care Medicine
, vol.160
, Issue.3
, pp. 899-905
-
-
Daniil, Z.D.1
Gilchrist, F.C.2
Nicholson, A.G.3
Hansell, D.M.4
Harris, J.5
Colby, T.V.6
Du, B.R.M.7
-
5
-
-
34547597339
-
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003
-
DOI 10.1164/rccm.200701-044OC
-
Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176:277-84. (Pubitemid 47195878)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.176
, Issue.3
, pp. 277-284
-
-
Olson, A.L.1
Swigris, J.J.2
Lezotte, D.C.3
Norris, J.M.4
Wilson, C.G.5
Brown, K.K.6
-
6
-
-
17644421000
-
-
Surveillance, Epidemiology, and End Results Program (SEER)
-
Surveillance, Epidemiology, and End Results Program (SEER). SEER cancer statistics review, 2003-2009 (http://seer.cancer.gov).
-
(2003)
SEER Cancer Statistics Review
-
-
-
7
-
-
77951160564
-
Pirfenidone in idiopathic pulmonary fibrosis
-
Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
-
(2010)
Eur Respir J
, vol.35
, pp. 821-829
-
-
Taniguchi, H.1
Ebina, M.2
Kondoh, Y.3
-
8
-
-
79956341531
-
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
-
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
-
(2011)
Lancet
, vol.377
, pp. 1760-1769
-
-
Noble, P.W.1
Albera, C.2
Bradford, W.Z.3
-
9
-
-
21744460289
-
Standardisation of spirometry
-
DOI 10.1183/09031936.05.00034805
-
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
-
(2005)
European Respiratory Journal
, vol.26
, Issue.2
, pp. 319-338
-
-
Miller, M.R.1
Hankinson, J.2
Brusasco, V.3
Burgos, F.4
Casaburi, R.5
Coates, A.6
Crapo, R.7
Enright, P.8
Van Der Grinten, C.P.M.9
Gustafsson, P.10
Jensen, R.11
Johnson, D.C.12
MacIntrye, N.13
McKay, R.14
Navajas, D.15
Pedersen, O.F.16
Pellegrino, R.17
Viegi, G.18
Wagner, J.19
-
10
-
-
33645762226
-
A sharper Bonferroni procedure for multiple tests of significance
-
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
-
(1988)
Biometrika
, vol.75
, pp. 800-802
-
-
Hochberg, Y.1
-
11
-
-
20944434994
-
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
-
DOI 10.1164/rccm.200404-571OC
-
Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7. (Pubitemid 40616955)
-
(2005)
American Journal of Respiratory and Critical Care Medicine
, vol.171
, Issue.9
, pp. 1040-1047
-
-
Azuma, A.1
Nukiwa, T.2
Tsuboi, E.3
Suga, M.4
Abe, S.5
Nakata, K.6
Taguchi, Y.7
Nagai, S.8
Itoh, H.9
Ohi, M.10
Sato, A.11
Kudoh, S.12
Raghu, G.13
-
12
-
-
84901793089
-
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
-
in press
-
Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology (in press).
-
Respirology
-
-
Valeyre, D.1
Albera, C.2
Bradford, W.Z.3
-
13
-
-
67650349068
-
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial
-
King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8.
-
(2009)
Lancet
, vol.374
, pp. 222-228
-
-
King Jr., T.E.1
Albera, C.2
Bradford, W.Z.3
-
14
-
-
84455168726
-
Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference
-
du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 1382-1389
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
15
-
-
79955520497
-
Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference
-
du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-7.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 1231-1237
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
16
-
-
0041874992
-
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis
-
DOI 10.1164/rccm.200211-1311OC
-
Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. (Pubitemid 37088595)
-
(2003)
American Journal of Respiratory and Critical Care Medicine
, vol.168
, Issue.5
, pp. 538-542
-
-
Collard, H.R.1
King Jr., T.E.2
Bartelson, B.B.3
Vourlekis, J.S.4
Schwarz, M.I.5
Brown, K.K.6
-
17
-
-
0041374153
-
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia
-
DOI 10.1164/rccm.200209-1112OC
-
Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8. (Pubitemid 37088596)
-
(2003)
American Journal of Respiratory and Critical Care Medicine
, vol.168
, Issue.5
, pp. 543-548
-
-
Flaherty, K.R.1
Mumford, J.A.2
Murray, S.3
Kazerooni, E.A.4
Gross, B.H.5
Colby, T.V.6
Travis, W.D.7
Flint, A.8
Toews, G.B.9
Lynch III, J.P.10
Martinez, F.J.11
-
18
-
-
20144381640
-
Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia
-
DOI 10.1164/rccm.200403-331OC
-
Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639-44. (Pubitemid 40365421)
-
(2005)
American Journal of Respiratory and Critical Care Medicine
, vol.171
, Issue.6
, pp. 639-644
-
-
Jegal, Y.1
Dong, S.K.2
Tae, S.S.3
Lim, C.-M.4
Sang, D.L.5
Koh, Y.6
Woo, S.K.7
Won, D.K.8
Jin, S.L.9
Travis, W.D.10
Kitaichi, M.11
Colby, T.V.12
-
19
-
-
13844316832
-
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis
-
DOI 10.1378/chest.127.1.171
-
King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7. (Pubitemid 41724573)
-
(2005)
Chest
, vol.127
, Issue.1
, pp. 171-177
-
-
King Jr., T.E.1
Safrin, S.2
Starko, K.M.3
Brown, K.K.4
Noble, P.W.5
Raghu, G.6
Schwartz, D.A.7
-
20
-
-
77951170794
-
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
-
Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2009;35:830-6.
-
(2009)
Eur Respir J
, vol.35
, pp. 830-836
-
-
Zappala, C.J.1
Latsi, P.I.2
Nicholson, A.G.3
-
21
-
-
84862826491
-
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
-
Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67:407-11.
-
(2012)
Thorax
, vol.67
, pp. 407-411
-
-
Richeldi, L.1
Ryerson, C.J.2
Lee, J.S.3
-
22
-
-
80051819865
-
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
-
du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-66.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 459-466
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
23
-
-
84899830690
-
6-Minute walk test distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
-
du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk test distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014;43:1421-9.
-
(2014)
Eur Respir J
, vol.43
, pp. 1421-1429
-
-
Du Bois, R.M.1
Albera, C.2
Bradford, W.Z.3
-
24
-
-
57949084974
-
Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis
-
Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009;103:117-23.
-
(2009)
Respir Med
, vol.103
, pp. 117-123
-
-
Caminati, A.1
Bianchi, A.2
Cassandro, R.3
Mirenda, M.R.4
Harari, S.5
-
25
-
-
69249235753
-
Small changes in six-minute walk distance are important in diffuse parenchymal lung disease
-
Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009;103:1430-5.
-
(2009)
Respir Med
, vol.103
, pp. 1430-1435
-
-
Holland, A.E.1
Hill, C.J.2
Conron, M.3
Munro, P.4
McDonald, C.F.5
-
26
-
-
76549135612
-
The 6 minute walk in idiopathic pulmonary fibrosis: Longitudinal changes and minimum important difference
-
Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010;65:173-7.
-
(2010)
Thorax
, vol.65
, pp. 173-177
-
-
Swigris, J.J.1
Wamboldt, F.S.2
Behr, J.3
-
27
-
-
84897459884
-
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials
-
King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014;189:825-31.
-
(2014)
Am J Respir Crit Care Med
, vol.189
, pp. 825-831
-
-
King Jr., T.E.1
Albera, C.2
Bradford, W.Z.3
|